| Page 1720 | Kisaco Research
 

Hyunsun Jo

CEO
Pin Therapeutics

Dr. Hyunsun Jo is an entrepreneur in the biopharmaceutical industry. He is currently a Founder and Chief Executive Officer at Pin Therapeutics, which is located in South San Francisco and South Korea. Pin Therapeutics is backed by many venture capitals in South Korea and actively developing integrative drug discovery platform at the field of protein degradation therapeutics using small molecules. Prior to founding Pin Therapeutics, Dr. Jo has founded two biotech companies called by a LabQnA and an Embedbio.

Hyunsun Jo

CEO
Pin Therapeutics

Hyunsun Jo

CEO
Pin Therapeutics

Dr. Hyunsun Jo is an entrepreneur in the biopharmaceutical industry. He is currently a Founder and Chief Executive Officer at Pin Therapeutics, which is located in South San Francisco and South Korea. Pin Therapeutics is backed by many venture capitals in South Korea and actively developing integrative drug discovery platform at the field of protein degradation therapeutics using small molecules. Prior to founding Pin Therapeutics, Dr. Jo has founded two biotech companies called by a LabQnA and an Embedbio. He obtained his BA and PhD in Molecular Biology (Metabolic Diseases) at Seoul National University and Postdoc (aging-related diseases) at the Gladstone Institute (UCSF).

 

Frank Mercurio

CSO
BioTheryX

Frank Mercurio has over 25 years of research experience studying the molecular mechanisms underlying cancer and inflammation. Frank was Senior Director of Discovery Biology at Celgene where he initiated and successfully managed numerous Target and Drug Discovery programs. Among his key discoveries, Frank’s team elucidated the mechanistic process regulating activation of the NF-kB signaling pathway, which plays a critical role in the onset and progression of many types of cancer and inflammation.

Frank Mercurio

CSO
BioTheryX

Frank Mercurio

CSO
BioTheryX

Frank Mercurio has over 25 years of research experience studying the molecular mechanisms underlying cancer and inflammation. Frank was Senior Director of Discovery Biology at Celgene where he initiated and successfully managed numerous Target and Drug Discovery programs. Among his key discoveries, Frank’s team elucidated the mechanistic process regulating activation of the NF-kB signaling pathway, which plays a critical role in the onset and progression of many types of cancer and inflammation. This program resulted in the identification of several novel therapeutic targets within the NF-kB pathway, creating several internal and partnered drug discovery programs. Frank also pioneered the development of an internal E3 Ubiquitin Ligase Program to identify small molecule modulators of protein degradation, an emerging area of drug development with enormous therapeutic potential. Another major focus of Frank's work was to develop technologies that enable the elucidation of drug mechanism of action. While at Celgene, he implemented these technologies to advance the understanding of Thalidomide and Lenalidomide mechanism of action. 

 

Fleur Ferguson

Assistant Professor
UCSD

Dr. Ferguson received her M.Sc in Chemistry from Imperial College London, and her Ph.D in Chemistry from the University of Cambridge. She performed her postdoctoral research in the laboratory of Professor Nathanael Gray at Harvard Medical School and Dana-Farber Cancer Institute. She is currently and Assistant Professor in the Department of Chemistry & Biochemistry and the Skaggs School of Pharmacy and Pharmaceutical Sciences at U.C. San Diego.

Fleur Ferguson

Assistant Professor
UCSD

Fleur Ferguson

Assistant Professor
UCSD

Dr. Ferguson received her M.Sc in Chemistry from Imperial College London, and her Ph.D in Chemistry from the University of Cambridge. She performed her postdoctoral research in the laboratory of Professor Nathanael Gray at Harvard Medical School and Dana-Farber Cancer Institute. She is currently and Assistant Professor in the Department of Chemistry & Biochemistry and the Skaggs School of Pharmacy and Pharmaceutical Sciences at U.C. San Diego.

 

Dhanusha Nalawansha

Postdoctoral Associate
Yale University

Dhanusha Nalawansha

Postdoctoral Associate
Yale University

Dhanusha Nalawansha

Postdoctoral Associate
Yale University
 

Derek Bartlett

Senior Principal Scientist
Pfizer

Derek Bartlett

Senior Principal Scientist
Pfizer

Derek Bartlett

Senior Principal Scientist
Pfizer
 

David Rubinsztein

Professor
Cambridge Institute for Medical Research

David Rubinsztein

Professor
Cambridge Institute for Medical Research

David Rubinsztein

Professor
Cambridge Institute for Medical Research
 

Daniel Scott

Research Specialist
St. Jude Children's Research Hospital

Daniel Scott

Research Specialist
St. Jude Children's Research Hospital

Daniel Scott

Research Specialist
St. Jude Children's Research Hospital
 

Christopher Kirk

President and CSO
Kezar Life Sciences Inc

Christopher Kirk

President and CSO
Kezar Life Sciences Inc

Christopher Kirk

President and CSO
Kezar Life Sciences Inc
 

Behnam Nabet

Research Fellow
Dana-Farber Cancer Institute

Behnam Nabet

Research Fellow
Dana-Farber Cancer Institute

Behnam Nabet

Research Fellow
Dana-Farber Cancer Institute
 

Andrew Benowitz

Senior Director, Protein Degradation DPU Head
GSK

Andrew Benowitz

Senior Director, Protein Degradation DPU Head
GSK

Andrew Benowitz

Senior Director, Protein Degradation DPU Head
GSK